Ottawa-born biotech startup Turnstone Biologics is halting all clinical studies, ceasing further development of its cutting-edge cancer-fighting viral treatments and exploring “strategic alternatives focused on maximizing shareholder value” that may include selling its assets, the company announced this week. Turnstone CEO Sammy Farah blamed rising manufacturing costs for the decision to shut down its remaining […]
Already an Insider? Log in
Get Instant Access to This Article
Become an Ottawa Business Journal Insider and get immediate access to all of our Insider-only content and much more.
